Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Articles

Page Path
HOME > Intest Res > Ahead-of print articles > Article
Original Article Association between remnant cholesterol and advanced colorectal adenoma in individuals under 50 years of age
Kwangmin Jooorcid, Jong Yoon Leeorcid, Jong Hoon Leeorcid

DOI: https://doi.org/10.5217/ir.2026.00093
Published online: June 11, 2026

Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea

Correspondence to Jong Yoon Lee, Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 49201, Korea. E-mail: ljyhateo@gmail.com
Co-Correspondence to Jong Hoon Lee, Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 49201, Korea. E-mail: jh2002@dau.ac.kr
• Received: March 18, 2026   • Revised: April 5, 2026   • Accepted: April 13, 2026

© 2026 Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 1,052 Views
  • 22 Download
Full Article

Download PDF Download PDF

  • Background/Aims
    The incidence of early-onset colorectal cancer is rising globally. While metabolic dysregulation is a known risk, the specific contribution of lipid profiles to colorectal carcinogenesis in young adults remains unclear. Remnant cholesterol (RC) has emerged as a significant cardiovascular risk factor, but its association with young-onset colorectal neoplasia is not fully elucidated.
  • Methods
    We conducted a retrospective, cross-sectional study of 4,100 asymptomatic individuals under 50 years of age undergoing screening colonoscopy. RC was calculated as total cholesterol minus high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. We used multivariate logistic regression to assess the independent association between RC levels and the presence of young-onset adenoma (YOA) and advanced YOA.
  • Results
    Patients with YOA had significantly higher RC levels than controls (17.65 ± 14.52 mg/dL vs. 14.69 ± 11.14 mg/dL; P< 0.001). In adjusted multivariate analysis, RC was independently associated with YOA risk (odds ratio [OR], 1.011; 95% confidence interval [CI], 1.003–1.019; P= 0.005). Notably, for advanced YOA, RC remained the only lipid parameter that retained statistical significance in the multivariable model (OR, 1.021; 95% CI, 1.004–1.038; P= 0.015), whereas traditional lipid markers were not significant.
  • Conclusions
    Higher RC levels were independently associated with YOA and advanced YOA in this cohort of asymptomatic individuals under 50 years of age. Among the lipid parameters examined, RC remained statistically significant in the multivariable model for advanced YOA.
  • Keywords: Remnant cholesterol; Colorectal neoplasms; Adenoma
The incidence of colorectal cancer (CRC) among individuals younger than 50 years of age, termed early-onset CRC (EOCRC), has been rising globally at an alarming rate [1]. This epidemiological shift presents a profound public health challenge, as EOCRC often presents at more advanced stages and exhibits distinct, aggressive clinicopathological features compared to late-onset CRC [1,2]. Given that most CRCs arise from precursor adenomas, the early identification and removal of young-onset adenomas (YOAs) are critical strategies for interrupting the adenoma-carcinoma sequence [3]. Although current guidelines have lowered the screening age to 45 years, a significant number of younger adults remain at risk, underscoring the need for precise risk stratification markers to identify those who would benefit from earlier or more intensive surveillance [4,5].
Metabolic dysregulation, characterized by obesity, insulin resistance, and dyslipidemia (DL), is a well-established risk factor for CRC [6]. Specifically, elevated triglyceride (TG) levels have been identified as an independent risk factor for colorectal polyp recurrence, particularly in cases of advanced YOA [7].
However, the specific contributions of lipid fractions to colorectal carcinogenesis remain unclear. Although low-density lipoprotein cholesterol (LDL-C) is the primary target for cardiovascular risk reduction, its association with colorectal adenoma remains inconsistent [8,9]. This suggests that traditional lipid profiles may not fully capture the atherogenic and potentially carcinogenic metabolic burdens in younger populations [9]. Furthermore, routine lipid panels often overlook the complex interplay between lipid metabolism and systemic inflammation, which is highly prevalent in young adults with westernized dietary habits [10,11].
Remnant cholesterol (RC), defined as the cholesterol content of TG-rich lipoproteins, has recently emerged as a significant risk factor for residual cardiovascular risk and all-cause mortality, independent of LDL-C [12]. Unlike fasting TG, which primarily reflect inert energy storage, RC represents the biologically active, cholesterol-enriched particles that can directly penetrate the endothelial and mucosal barriers. Once localized within tissues, these remnant particles are readily engulfed by macrophages, driving foam cell formation and creating a highly pro-inflammatory microenvironment [13,14]. Biologically, these remnant lipoproteins induce low-grade systemic inflammation and oxidative stress, mechanisms that share pathophysiology with tumor promotion [15,16]. Despite this plausibility, data regarding the specific association between RC and the risk of colorectal neoplasia in young adults are scarce.
We hypothesized that RC may be associated with young-onset colorectal adenomatous lesions and could provide additional information beyond conventional lipid parameters. Therefore, we investigated the association between serum RC levels and YOA, particularly advanced YOA, in asymptomatic individuals younger than 50 years undergoing screening colonoscopy.
1. Study Design and Population
This retrospective, cross-sectional study analyzed data from asymptomatic individuals younger than 50 years of age who underwent screening colonoscopy at the Health Screening Center of Dong-A University Hospital. The study period spanned from January 2018 to December 2024. Initially, we identified 6,025 eligible participants for this study. To ensure a homogeneous study population and accurate metabolic analysis, we applied the following exclusion criteria: (1) a history of prior colonoscopy (n=1,523); (2) a family history of CRC in a first-degree relative (n=346); (3) serum TG levels exceeding 500 mg/dL (n =43), as extreme hypertriglyceridemia precludes the reliable calculation of RC; and (4) missing clinical data (n =13). After applying these criteria, 4,100 participants were included in the final analysis (Fig. 1). In addition, no patients in the final study population were newly diagnosed with CRC at the index colonoscopy.
2. Definitions of Variables
Clinical data, including age, sex, and medical history, were retrieved from electronic medical records and self-reported questionnaires. Body mass index (BMI) was calculated as weight in kilograms divided by height squared in meters (kg/m2). Lifestyle factors, including smoking status and alcohol consumption, were evaluated using a standardized questionnaire. Smoking status was stratified as never, former, or current smoker. Comorbidities such as hypertension (HTN), diabetes mellitus, and DL were defined by a prior physician diagnosis or current use of relevant medications.
Venous blood samples were collected following an overnight fast of ≥ 8 hours on the same day as colonoscopy as part of the health screening evaluation. Serum concentrations of total cholesterol (TC), TG, high-density lipoprotein cholesterol (HDL-C), LDL-C, and fasting glucose were quantified using automated enzymatic assays. RC was calculated as TC–HDL-C–LDL-C. Although this calculated value is closely related to TG/5 when LDL-C is derived using the Friedewald equation in fasting samples, RC is conceptually intended to reflect the cholesterol content of TG-rich remnant lipoproteins rather than TG quantity itself.
YOA was defined as the presence of at least one histologically confirmed adenoma (tubular, villous, villo-tubular, or serrated) in individuals younger than 50 years of age. Advanced YOA was defined as an adenoma presenting with at least one of the following high-risk features: a diameter of 10 mm or larger, the presence of a villous component, or high-grade dysplasia.
3. Primary Endpoint
The primary endpoint of this study was to investigate the independent association between serum RC levels and the presence of YOA, compared with a control group without adenomas. Additionally, we evaluated the association between RC and the risk of advanced YOA to assess the potential of RC as a metabolic marker for the severity of colorectal neoplasia.
4. Statistics and Data Analysis
Statistical analyses were performed using SPSS software (version 26.0; IBM Corp., Armonk, NY, USA) and R software (version 4.5.3; R Foundation for Statistical Computing, Vienna, Austria). Continuous variables are expressed as means±standard deviations, and categorical variables as frequencies and percentages. Differences in baseline characteristics between the groups were compared using the Student t-test for continuous variables and the chi-square test for categorical variables. To identify independent risk factors associated with YOA and advanced YOA, univariate and multivariate logistic regression analyses were performed. Variables with a P-value of less than 0.05 in the univariate analysis were included in the multivariate models. Because RC was calculated as TC−HDL-C−LDL-C, it was not entered into the same multivariable model together with its component lipid variables, in order to avoid structural multicollinearity. Accordingly, RC was evaluated in a separate multivariable model from conventional lipid parameters. In addition, pairwise correlation analyses and collinearity diagnostics were performed to assess potential multicollinearity among the covariates included in the final models. Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). All P-values were two-sided, and a P-value of less than 0.05 was considered to indicate statistical significance.
5. IRB Approval
The study protocol was approved by the Institutional Review Board (IRB) of Dong-A University Hospital (IRB No. DAUHIRB-25-117) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the IRB due to the retrospective nature of the study and the use of anonymized clinical data.
1. Baseline Characteristics of the Study Population
The baseline characteristics of the study population are presented in Table 1. The mean age of the patients in the YOA group was significantly higher than that of the control group (41.42±5.55 years vs. 38.51±6.37 years; P<0.001). The proportion of males was also higher in the case group (66.7% vs. 53.5%; P<0.001). There were also significant differences between the 2 groups with respect to BMI, fasting glucose levels, and levels of TC, HDL-C, LDL-C (all P<0.001). Additionally, the level of RC was significantly higher in the YOA group than in the control group (17.65 ±14.52 mg/dL vs. 14.69 ±11.14 mg/dL; P<0.001). Similarly, the TG level was significantly elevated in the case group compared with the control group (129.59 ± 83.26 mg/dL vs. 111.87 ± 70.41 mg/dL; P<0.001). Regarding lifestyle factors and medical history, participants with YOA were more likely to be current smokers (26.3% vs. 18.4%; P<0.001) and to consume alcohol (52.4% vs. 47.8%; P=0.017) than those in the control group. The prevalence of HTN and DL was also significantly higher in the case group (P<0.001 and P=0.015, respectively), whereas the prevalence of diabetes mellitus did not differ significantly between the 2 groups.
2. Univariate and Multivariate Analyses of YOAs
In the univariate logistic regression analysis, age, male sex, higher BMI, and higher levels of fasting glucose were significantly associated with the presence of YOA (P<0.05 for all comparisons). Lipid profiles, including levels of TC, LDL-C, TG, and RC, were also significantly higher in patients with YOA than in controls. Variables that were significant in the univariate analysis were entered into the multivariable logistic regression model (Table 2). Age was a significant predictor of YOA (adjusted OR, 1.082; 95% CI, 1.067–1.097; P <0.001). Male sex was also strongly associated with an increased risk (adjusted OR, 1.614; 95% CI, 1.310–1.987; P<0.001). Among lifestyle factors and comorbidities, current smoking (adjusted OR, 1.250; 95% CI, 1.003–1.558; P=0.047) and a history of HTN (adjusted OR, 1.417; 95% CI, 1.046–1.918; P=0.024) remained significant in the multivariate model. In the multivariable model, RC remained significantly associated with YOA (adjusted OR, 1.011; 95% CI, 1.003–1.019; P=0.005). TC and LDL-C were evaluated in separate multivariable models and were both significantly associated with YOA. In additional analyses, pairwise correlation and collinearity diagnostics did not indicate problematic multicollinearity in the final multivariable model for YOA (Supplementary Tables 1 and 2).
3. Univariate and Multivariate Analyses of Advanced YOAs
We further analyzed risk factors associated with advanced YOA. In the univariate analysis, older age (OR, 1.095; 95% CI, 1.038–1.156; P=0.001) and HTN (OR, 4.421; 95% CI, 2.102–9.294; P<0.001) were significantly associated with advanced YOA. Among lipid parameters, TC (P=0.043), RC (P=0.005), and DL (P= 0.032) were significant, whereas LDL-C (P= 0.157) and TG (P=0.106) were not. In the multivariable analysis, age (adjusted OR, 1.080; 95% CI, 1.022–1.141; P=0.006) and HTN (adjusted OR, 3.123; 95% CI, 1.432–6.810; P=0.004) remained significantly associated with advanced YOA. Among lipid parameters, TC and DL were no longer significant, whereas RC remained significantly associated with advanced YOA (adjusted OR, 1.021; 95% CI, 1.004–1.038; P=0.015) (Table 3). In additional analyses, collinearity diagnostics did not indicate problematic multicollinearity in the final multivariable model for advanced YOA (Supplementary Table 2).
4. Additional Analysis Using Sex-Specific Low HDL-C Thresholds
In an additional analysis using sex-specific HDL-C thresholds, low HDL-C was defined as HDL-C <40 mg/dL in men and <50 mg/dL in women. Because RC was calculated from conventional lipid components, sex-specific low HDL-C was evaluated in a separate model rather than simultaneously with RC. In these additional analyses, low HDL-C was not independently associated with either YOA or advanced YOA (Supplementary Table 3).
In this study of 4,100 asymptomatic individuals under 50 years of age, higher RC levels were independently associated with YOA. In addition, RC remained significantly associated with advanced YOA in the multivariable analysis, whereas TC and LDL-C were not. These findings suggest that RC may reflect a metabolic profile associated with YOA and advanced YOA in this population.
The incidence of EOCRC is rising globally, necessitating more precise risk stratification strategies beyond age and family history [17]. While metabolic syndrome and insulin resistance are established risk factors for colorectal neoplasia, the specific contribution of individual lipid components has remained debated [18-20]. Our findings suggest that the association between RC and YOA is maintained independent of LDL-C [9]. In our analysis of YOA, although TG lost statistical significance after adjustment, RC remained significant. This suggests that RC may reflect aspects of TG-rich lipoprotein metabolism that are not fully captured by TG levels alone. This distinction may be relevant given the inconsistent evidence linking traditional lipid profiles to colorectal neoplasia. RC may therefore warrant further evaluation as a metabolic marker in this context [21,22]. Recent studies have suggested a link between RC and colorectal carcinogenesis [23,24]. In a 2024 study combining cross-sectional and Mendelian randomization analyses, RC was associated with CRC risk [23]. In addition, a more recent prospective cohort study reported that elevated RC was associated with a higher long-term risk of overall cancer, including CRC, and that this association was more pronounced in the presence of systemic inflammation [24]. In this context, our findings extend the literature by focusing on adenomatous precursor lesions, particularly YOA and advanced YOA, in asymptomatic individuals younger than 50 years.
A possible explanation for our findings is that RC reflects the cholesterol carried within TG-rich remnant lipoproteins, which may provide information distinct from that captured by TG, TC, or LDL-C alone. These remnant particles may be more closely related to low-grade inflammation, oxidative stress, and insulin resistance, all of which are biologically relevant to colorectal neoplasia [25,26]. Chronic low-grade inflammation, mediated by cytokines such as tumor necrosis factor-α and interleukin-6, is a known driver of colorectal tumorigenesis [27-29]. Furthermore, RC is closely linked to insulin resistance [30]. Hyperinsulinemia increases the bioavailability of insulin-like growth factor-1, which promotes cell proliferation and inhibits apoptosis in colonic epithelial cells [31,32]. Our finding that RC is associated with advanced YOA—lesions with a higher potential for malignant transformation—provides biological plausibility for a possible link between remnant lipoproteins and neoplastic development through these metabolic and inflammatory pathways. This is consistent with the broader understanding that metabolic dysregulation, including insulin resistance and chronic systemic inflammation, may contribute to early-onset colorectal carcinogenesis [33].
A distinguishing feature of our study is the association observed specifically in the advanced YOA group. In this subgroup, HTN and RC were the only significant modifiable risk factors. While LDL-C is the primary target for cardiovascular prevention, its role in CRC is inconsistent [9]. Our data showed that LDL-C was not a significant predictor for advanced lesions in the multivariate analysis. This may suggest that, in young adults, RC may reflect metabolic characteristics associated with advanced colorectal neoplasia beyond those captured by conventional lipid parameters, although this interpretation should be made cautiously given the interdependence among lipid measures. This highlights the potential relevance of specific lipid subfractions, such as RC, which may provide additional insight into metabolic perturbations associated with early-onset colorectal neoplasia beyond broadly measured lipid parameters [34,35].
Our study has several methodological strengths. We enforced strict exclusion criteria, specifically removing subjects with extreme hypertriglyceridemia ( >500 mg/dL). This approach reduced the potential influence of extreme metabolic outliers, addressing a common limitation of retrospective studies evaluating lipid parameters. Furthermore, the inclusion of a large cohort of strictly asymptomatic young adults undergoing screening colonoscopy minimizes the selection bias often associated with diagnostic colonoscopy studies. Additionally, adjustment for a wide range of potential confounders—including lifestyle factors, comorbidities, and traditional lipid markers—strengthened the robustness of the observed association between RC and advanced YOA.
However, there are limitations to consider. First, this was a single-center, retrospective study, which limits the ability to infer causality and generalize findings to other ethnic groups. Prospective, multicenter studies with direct RC measurements are needed to validate these findings and further investigate the underlying biological mechanisms. Second, because the study population was restricted to individuals younger than 50 years of age, we were unable to directly compare the association between RC and colorectal neoplasia across age groups. Therefore, the present findings should not be interpreted as demonstrating that this association is unique to YOA. Third, RC was calculated rather than directly measured. Although calculated RC is a widely accepted surrogate in large epidemiological studies, direct quantification could provide greater precision. In addition, because RC was derived from conventional lipid components, it is intrinsically interrelated with TC, HDL-C, and LDL-C. Therefore, although we used separate multivariable models to reduce structural multicollinearity, comparisons between RC and conventional lipid parameters should be interpreted cautiously. Similarly, DL history may partly reflect the underlying lipid abnormalities captured by RC. In addition, while we adjusted for smoking and alcohol, we could not account for dietary habits or physical activity, which are unmeasured confounders sharing a link with both lipid levels and adenoma risk. Finally, the number of advanced YOA cases was relatively small, although the association with RC remained statistically significant.
In conclusion, higher RC levels were independently associated with YOA, particularly advanced YOA, in asymptomatic individuals younger than 50 years. Our findings suggest that RC may provide additional information beyond traditional lipid markers in this specific population. Further studies are needed to determine whether RC may have a role in risk stratification for colorectal neoplasia in young adults.

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Data Availability Statement

Data analyzed in this study are available from the corresponding author upon reasonable request.

Author Contributions

Conceptualization: Lee JY. Data curation: Joo K. Formal analysis: Joo K, Lee JY. Funding acquisition: Lee JY. Investigation; Methodology: Joo K, Lee JY. Project administration: Lee JH, Lee JY. Resources; Software: Joo K, Lee JY. Supervision; Validation: Lee JH. Visualization: Joo K, Lee JY. Writing–original draft: Joo K, Lee JY. Writing–review & editing: all authors. Approval of final manuscript: all authors.

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Pairwise Correlations among Candidate Variables Included in the Multivariable Analyses
ir-2026-00093-Supplementary-Table-1.pdf

Supplementary Table 2.

Collinearity Diagnostics for the Final Multivariable Models for YOA and Advanced YOA
ir-2026-00093-Supplementary-Table-2.pdf

Supplementary Table 3.

Additional Analyses Using Sex-Specific Low HDL-C Categories for YOA and Advanced YOA
ir-2026-00093-Supplementary-Table-3.pdf
Fig. 1.
Flowchart of the study population selection. A total of 6,025 individuals aged <50 years who underwent screening colonoscopy at Dong-A University Hospital between 2018 and 2024 were initially assessed. After excluding 1,925 subjects based on predefined criteria, including prior colonoscopy history (n=1,523), family history of colorectal cancer in first-degree relatives (n=346), high serum triglyceride levels (n=43), and missing data (n=13), a final cohort of 4,100 participants was included in the analysis.
ir-2026-00093f1.jpg
ir-2026-00093f2.jpg
Table 1.
Baseline Characteristics of the Study Population
Characteristic All patients (n=4,100) Control (n=3,229) Patients with YOA (n=871) P-value
Age (yr) 39.13±6.32 38.51±6.37 41.42±5.55 <0.001
Male sex 2,310 (56.3) 1,729 (53.5) 581 (66.7) <0.001
BMI (kg/m2) 24.00±4.91 23.85±5.14 24.54±3.85 <0.001
Fasting glucose (mg/dL) 90.66±16.86 89.96±16.76 93.24±16.97 <0.001
HDL-C (mg/dL) 56.66±13.55 57.10±13.47 55.04±13.72 <0.001
LDL-C (mg/dL) 128.10±30.41 126.68±30.05 133.38±31.12 <0.001
TG (mg/dL) 115.64±73.68 111.87±70.41 129.59±83.26 <0.001
TC (mg/dL) 200.08±36.44 198.47±35.93 206.07±37.70 <0.001
RC (mg/dL) 15.32±12.00 14.69±11.14 17.65±14.52 <0.001
Alcohol consumption 2,000 (48.8) 1,544 (47.8) 456 (52.4) 0.017
Smoking status <0.001
 Non-smoker 2,532 (61.8) 2,073 (64.2) 459 (52.7)
 Ex-smoker 745 (18.2) 562 (17.4) 183 (21.0)
 Current smoker 823 (20.1) 594 (18.4) 229 (26.3)
Medical history
 HTN 226 (5.5) 146 (4.5) 80 (9.2) <0.001
 DM 85 (2.1) 63 (2.0) 22 (2.5) 0.289
 DL 127 (3.1) 89 (2.8) 38 (4.4) 0.015

Values are presented as mean±standard deviation or number (%).

YOA, young-onset adenoma; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; RC, remnant cholesterol; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia.

Table 2.
Univariate and Multivariate Analyses Related to Young-Onset Adenoma
Characteristics Univariate
 Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age 1.083 (1.069–1.097) <0.001 1.082 (1.067–1.097) <0.001
Male sex 1.738 (1.486–2.034) <0.001 1.614 (1.310–1.987) <0.001
BMI 1.031 (1.012–1.051) 0.001 1.002 (0.986–1.018) 0.842
Fasting glucose 1.010 (1.006–1.014) <0.001 1.002 (0.997–1.007) 0.424
HDL-C 0.988 (0.983–0.994) <0.001 0.998 (0.991–1.004) 0.485
LDL-C 1.007 (1.005–1.010) <0.001 1.003 (1.001–1.006) 0.008
TG 1.003 (1.002–1.004) <0.001 1.000 (0.999–1.001) 0.950
TC 1.006 (1.004–1.008) <0.001 1.003 (1.001–1.005) 0.002
RC 1.019 (1.013–1.025) <0.001 1.011 (1.003–1.019) 0.005
Alcohol consumption 1.199 (1.032–1.393) 0.018 0.965 (0.815–1.142) 0.677
Smoking status <0.001 0.091
 Ex-smoker 1.471 (1.210–1.787) <0.001 1.007 (0.803–1.263) 0.953
 Current smoker 1.741 (1.450–2.091) <0.001 1.250 (1.003–1.558) 0.047
Medical history
 HTN 2.138 (1.610–2.840) <0.001 1.417 (1.046–1.918) 0.024
 DM 1.304 (0.798–2.131) 0.290
 DL 1.609 (1.093–2.371) 0.016 1.027 (0.684–1.542) 0.897

TC and LDL-C were evaluated in separate multivariable models and were both significantly associated with young-onset adenoma.

OR, odds ratio; CI, confidence interval; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; RC, remnant cholesterol; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia.

Table 3.
Univariate and Multivariate Analyses Related to Advanced Young-Onset Adenoma
Characteristic Univariate
 Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age 1.095 (1.038–1.156) 0.001 1.080 (1.022–1.141) 0.006
Male sex 1.726 (0.915–3.253) 0.092
BMI 1.010 (0.976–1.045) 0.558
Fasting glucose 1.010 (0.999–1.021) 0.077
HDL-C 0.996 (0.975–1.019) 0.751
LDL-C 1.007 (0.997–1.016) 0.157
TG 1.003 (0.999–1.006) 0.106
TC 1.007 (1.000–1.014) 0.043 1.007 (1.000–1.014) 0.065
RC 1.023 (1.007–1.039) 0.005 1.021 (1.004–1.038) 0.015
Alcohol consumption 1.004 (0.558–1.808) 0.988
Smoking status 0.337
 Ex-smoker 0.951 (0.410–2.208) 0.907
 Current smoker 1.609 (0.820–3.161) 0.167
Medical history
 HTN 4.421 (2.102–9.294) <0.001 3.123 (1.432–6.810) 0.004
 DM 1.074 (0.146–7.888) 0.944
 DL 3.119 (1.100–8.844) 0.032 0.587 (0.197–1.745) 0.338

TC and LDL-C were evaluated in separate multivariable models and were both significantly associated with young-onset adenoma.

OR, odds ratio; CI, confidence interval; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; RC, remnant cholesterol; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia.

  • 1. Akimoto N, Ugai T, Zhong R, et al. Rising incidence of early-onset colorectal cancer: a call to action. Nat Rev Clin Oncol 2021;18:230–243.ArticlePubMedPMCPDF
  • 2. Zhang J, Ou D, Xie A, Chen D, Li X. Global burden and crosscountry health inequalities of early-onset colorectal cancer and its risk factors from 1990 to 2021 and its projection until 2036. BMC Public Health 2024;24:3124.ArticlePubMedPMCPDF
  • 3. Zaborowski AM, REACCT Collaborative. Colorectal cancer in the young: Research in Early Age Colorectal Cancer Trends (REACCT) Collaborative. Cancers (Basel) 2023;15:2979.ArticlePubMedPMC
  • 4. Khader M, Delgado JS, Artoul R, Shafrir A, Naim AF. Insights from age-stratified endoscopic detection metrics support initiating colorectal cancer screening at age 45. BMC Gastroenterol 2025;25:597.ArticlePubMedPMCPDF
  • 5. Kim I, Lee HH, Ko YJ, et al. Factors associated with the risk of colorectal neoplasia in young adults under age 40. Korean J Intern Med 2022;37:969–978.ArticlePubMedPMCPDF
  • 6. Dekker E, Tanis PJ, Vleugels JL, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019;394:1467–1480.ArticlePubMed
  • 7. Tabuchi M, Kitayama J, Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol 2006;12:1261–1264.ArticlePubMedPMC
  • 8. Bull CJ, Bell JA, Murphy N, et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Med 2020;18:396.PubMedPMC
  • 9. Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. Br J Cancer 2021;124:663–670.ArticlePubMedPMCPDF
  • 10. Močnik M, Marčun Varda N. Lipid biomarkers and atherosclerosis-old and new in cardiovascular risk in childhood. Int J Mol Sci 2023;24:2237.ArticlePubMedPMC
  • 11. Tahir UA, Gerszten RE. Molecular biomarkers for cardiometabolic disease: risk assessment in young individuals. Circ Res 2023;132:1663–1673.ArticlePubMedPMC
  • 12. Zhao Y, Zhuang Z, Li Y, et al. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun 2024;15:2451.ArticlePubMedPMCPDF
  • 13. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345–1361.ArticlePubMedPMC
  • 14. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009;16:145–154.ArticlePubMed
  • 15. Guan B, Wang A, Xu H. Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors: a mendelian randomization analysis. Cardiovasc Diabetol 2023;22:207.ArticlePubMedPMCPDF
  • 16. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 2019;40:537–557.ArticlePubMedPMC
  • 17. Medici B, Riccò B, Caffari E, et al. Early onset metastatic colorectal cancer: current insights and clinical management of a rising condition. Cancers (Basel) 2023;15:3509.ArticlePubMedPMC
  • 18. Choi CH, Moon SY, Lee JY. The relationship between surrogate markers of insulin resistance and occurrence of colorectal adenoma in individuals under 50 years old: a single-center retrospective cross-sectional study. J Pers Med 2024;14:971.ArticlePubMedPMC
  • 19. Hofseth LJ, Hebert JR, Chanda A, et al. Early-onset colorectal cancer: initial clues and current views. Nat Rev Gastroenterol Hepatol 2020;17:352–364.ArticlePubMedPMCPDF
  • 20. Xie C, Wen P, Su J, et al. Elevated serum triglyceride and low-density lipoprotein cholesterol promotes the formation of colorectal polyps. BMC Gastroenterol 2019;19:195.ArticlePubMedPMCPDF
  • 21. Chan WC, Liu L, Bouras E, et al. Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study. Br J Cancer 2025;132:103–110.ArticlePubMedPMCPDF
  • 22. Niu S, Jiang C, Miao X, Zhang Y, Li Z, Wang T. Association of triglyceride-glucose related indices with colorectal cancer risk among the US population: a cross-sectional study. BMC Cancer 2025;25:1186.ArticlePubMedPMCPDF
  • 23. Li M, Liu Q, Shi M, Fu M, He G. Association between remnant cholesterol and the risk of 4 site-specific cancers: evidence from a cross-sectional and Mendelian randomization study. Lipids Health Dis 2024;23:256.ArticlePubMedPMCPDF
  • 24. Xu H, Liu P, Chen S, Wang G, Wu S, Zhang X. Remnant cholesterol and systemic inflammation as synergistic predictors of cancer risk: a 16-year prospective cohort study. Cancer 2025;131:e70096.ArticlePubMed
  • 25. Burgos-Molina AM, Téllez Santana T, Redondo M, Bravo Romero MJ. The crucial role of inflammation and the immune system in colorectal cancer carcinogenesis: a comprehensive perspective. Int J Mol Sci 2024;25:6188.ArticlePubMedPMC
  • 26. Daveri E, Vergani B, Lalli L, et al. Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesis. J Immunother Cancer 2024;12:e009720.ArticlePubMedPMC
  • 27. Li Y, Luo Y, Ran Y, Lu F, Qin Y. Biomarkers of inflammation and colorectal cancer risk. Front Oncol 2025;15:1514009.ArticlePubMedPMC
  • 28. Soundararajan R, Maurin MM, Rodriguez-Silva J, et al. Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer. Gut 2025;74:586–602.ArticlePubMedPMC
  • 29. Vahed IE, Esmaili Z, Mamaghani MP, et al. The association between serum lipid levels and colorectal cancer risk: a dose-response meta-analysis of 23 studies. PLoS One 2025;20:e0333907.ArticlePubMedPMC
  • 30. Li W, Liu T, Qian L, et al. Insulin resistance and inflammation mediate the association of abdominal obesity with colorectal cancer risk. Front Endocrinol (Lausanne) 2022;13:983160.ArticlePubMedPMC
  • 31. Kasprzak A. Insulin-like growth factor 1 (IGF-1) signaling in glucose metabolism in colorectal cancer. Int J Mol Sci 2021;22:6434.ArticlePubMedPMC
  • 32. Li Q, Geng S, Luo H, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Ther 2024;9:266.ArticlePubMedPMCPDF
  • 33. Chen H, Zheng X, Zong X, et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut 2021;70:1147–1154.ArticlePubMedPMC
  • 34. Chang YH, Shin CM, Han K, et al. The persistence of hypertriglyceridemia and the risk of early onset colorectal cancer according to tumor subsites: a nationwide population-based study. Cancer Res Treat 2024;56:825–837.ArticlePubMedPMCPDF
  • 35. Han M, Wang H, Yang S, et al. Triglyceride glucose index and Atherogenic index of plasma for predicting colorectal neoplasms in patients without cardiovascular diseases. Front Oncol 2022;12:1031259.ArticlePubMedPMC

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Association between remnant cholesterol and advanced colorectal adenoma in individuals under 50 years of age
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      Association between remnant cholesterol and advanced colorectal adenoma in individuals under 50 years of age
      Image Image
      Fig. 1. Flowchart of the study population selection. A total of 6,025 individuals aged <50 years who underwent screening colonoscopy at Dong-A University Hospital between 2018 and 2024 were initially assessed. After excluding 1,925 subjects based on predefined criteria, including prior colonoscopy history (n=1,523), family history of colorectal cancer in first-degree relatives (n=346), high serum triglyceride levels (n=43), and missing data (n=13), a final cohort of 4,100 participants was included in the analysis.
      Graphical abstract

      Fig. 1.

      Graphical abstract

      Association between remnant cholesterol and advanced colorectal adenoma in individuals under 50 years of age
      Characteristic All patients (n=4,100) Control (n=3,229) Patients with YOA (n=871) P-value
      Age (yr) 39.13±6.32 38.51±6.37 41.42±5.55 <0.001
      Male sex 2,310 (56.3) 1,729 (53.5) 581 (66.7) <0.001
      BMI (kg/m2) 24.00±4.91 23.85±5.14 24.54±3.85 <0.001
      Fasting glucose (mg/dL) 90.66±16.86 89.96±16.76 93.24±16.97 <0.001
      HDL-C (mg/dL) 56.66±13.55 57.10±13.47 55.04±13.72 <0.001
      LDL-C (mg/dL) 128.10±30.41 126.68±30.05 133.38±31.12 <0.001
      TG (mg/dL) 115.64±73.68 111.87±70.41 129.59±83.26 <0.001
      TC (mg/dL) 200.08±36.44 198.47±35.93 206.07±37.70 <0.001
      RC (mg/dL) 15.32±12.00 14.69±11.14 17.65±14.52 <0.001
      Alcohol consumption 2,000 (48.8) 1,544 (47.8) 456 (52.4) 0.017
      Smoking status <0.001
       Non-smoker 2,532 (61.8) 2,073 (64.2) 459 (52.7)
       Ex-smoker 745 (18.2) 562 (17.4) 183 (21.0)
       Current smoker 823 (20.1) 594 (18.4) 229 (26.3)
      Medical history
       HTN 226 (5.5) 146 (4.5) 80 (9.2) <0.001
       DM 85 (2.1) 63 (2.0) 22 (2.5) 0.289
       DL 127 (3.1) 89 (2.8) 38 (4.4) 0.015
      Characteristics Univariate
      		 Multivariate
      OR (95% CI) P-value OR (95% CI) P-value
      Age 1.083 (1.069–1.097) <0.001 1.082 (1.067–1.097) <0.001
      Male sex 1.738 (1.486–2.034) <0.001 1.614 (1.310–1.987) <0.001
      BMI 1.031 (1.012–1.051) 0.001 1.002 (0.986–1.018) 0.842
      Fasting glucose 1.010 (1.006–1.014) <0.001 1.002 (0.997–1.007) 0.424
      HDL-C 0.988 (0.983–0.994) <0.001 0.998 (0.991–1.004) 0.485
      LDL-C 1.007 (1.005–1.010) <0.001 1.003 (1.001–1.006) 0.008
      TG 1.003 (1.002–1.004) <0.001 1.000 (0.999–1.001) 0.950
      TC 1.006 (1.004–1.008) <0.001 1.003 (1.001–1.005) 0.002
      RC 1.019 (1.013–1.025) <0.001 1.011 (1.003–1.019) 0.005
      Alcohol consumption 1.199 (1.032–1.393) 0.018 0.965 (0.815–1.142) 0.677
      Smoking status <0.001 0.091
       Ex-smoker 1.471 (1.210–1.787) <0.001 1.007 (0.803–1.263) 0.953
       Current smoker 1.741 (1.450–2.091) <0.001 1.250 (1.003–1.558) 0.047
      Medical history
       HTN 2.138 (1.610–2.840) <0.001 1.417 (1.046–1.918) 0.024
       DM 1.304 (0.798–2.131) 0.290
       DL 1.609 (1.093–2.371) 0.016 1.027 (0.684–1.542) 0.897
      Characteristic Univariate
      		 Multivariate
      OR (95% CI) P-value OR (95% CI) P-value
      Age 1.095 (1.038–1.156) 0.001 1.080 (1.022–1.141) 0.006
      Male sex 1.726 (0.915–3.253) 0.092
      BMI 1.010 (0.976–1.045) 0.558
      Fasting glucose 1.010 (0.999–1.021) 0.077
      HDL-C 0.996 (0.975–1.019) 0.751
      LDL-C 1.007 (0.997–1.016) 0.157
      TG 1.003 (0.999–1.006) 0.106
      TC 1.007 (1.000–1.014) 0.043 1.007 (1.000–1.014) 0.065
      RC 1.023 (1.007–1.039) 0.005 1.021 (1.004–1.038) 0.015
      Alcohol consumption 1.004 (0.558–1.808) 0.988
      Smoking status 0.337
       Ex-smoker 0.951 (0.410–2.208) 0.907
       Current smoker 1.609 (0.820–3.161) 0.167
      Medical history
       HTN 4.421 (2.102–9.294) <0.001 3.123 (1.432–6.810) 0.004
       DM 1.074 (0.146–7.888) 0.944
       DL 3.119 (1.100–8.844) 0.032 0.587 (0.197–1.745) 0.338
      Table 1. Baseline Characteristics of the Study Population

      Values are presented as mean±standard deviation or number (%).

      YOA, young-onset adenoma; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; RC, remnant cholesterol; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia.

      Table 2. Univariate and Multivariate Analyses Related to Young-Onset Adenoma

      TC and LDL-C were evaluated in separate multivariable models and were both significantly associated with young-onset adenoma.

      OR, odds ratio; CI, confidence interval; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; RC, remnant cholesterol; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia.

      Table 3. Univariate and Multivariate Analyses Related to Advanced Young-Onset Adenoma

      TC and LDL-C were evaluated in separate multivariable models and were both significantly associated with young-onset adenoma.

      OR, odds ratio; CI, confidence interval; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; RC, remnant cholesterol; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia.

      Table 1.

      Table 2.

      Table 3.

      Intest Res : Intestinal Research
      © Korean Association for the Study of Intestinal Diseases.
      Close layer
      TOP